centrosomal protein 170 pseudogene 1Genealiases: CEP170L · FAM68B · KIAA0470L
Q-omics provides the consensus-scored CEP170P1 profile across patient tissues and cancer cell-line models. CEP170P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CEP170P1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CEP170P1 RNA expression shows 19,235 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where CEP170P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP170P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP170P1 survival associations across molecular data types. CEP170P1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP170P1 RNA expression–survival associations across cancer types. High CEP170P1 expression shows unfavorable associations in MESO, UVM, ACC and STAD, but favorable associations in KIRC and PRAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CEP170P1 RNA expression.
This table summarizes CEP170P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CEP170P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP170P1 shows lower tumor expression in COAD and THCA and higher tumor expression in HNSC, KIRC, KIRP and STAD. The HNSC box plot shows higher CEP170P1 RNA expression in tumor versus normal tissue (log2 FC = +0.143, t-test p < 0.001).
This table shows molecular features associated with CEP170P1 in patient tissues and cancer cell lines. In patient samples, CEP170P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP170P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH.
